Study Title
informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia
Purpose
To describe current treatment patterns in the real-world setting among CLL patients who are beginning treatment with approved oral kinase inhibitors or other approved anti-CLL therapies/regimens as well as any association with patient characteristics, healthcare resource utilization, clinical outcomes, & patient-reported outcomes.
Eligibility
At least 18 years of age
Clinical diagnosis of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)
Beginning treatment within +/- 30 days of enrollment
Willing & able to provide written informed consent
Willing & able to complete patient reported outcome questionnaires
Willing & able to provide information on patient survey questionnaires
Willing to provide a blood sample at time of enrollment
You Cannot:
Be diagnosed with any B-Cell malignancy other than CLL/SLL
Have a life expectancy of less than 6 months
Study Process
Relevant data will be retrieved from the patient medical record & recorded into the registry electronic case report forms along with the completion of the patient reported outcome quesationniare :
Baseline
Every 3 months for the 1st 6 months
Every 6 months thereafter for a minimum of 2 years
Interested in more information on this clinical research study?
Contact WK Cancer Center Clinical Research Department at 318-212-8671
Trial Details
Investigator:
IRB:
Advarra Institutional Review Board
IRB Number:
Trial Type:
NA
Sponsor:
Pharmacyclics LLC
Contact Information:
Hematology Oncology Associates
Interested in Volunteering for the Study?
If you would like more information about this study, please call us at (318) 212-8671.